Research Topics
| F BalkwillSummaryAffiliation: Cancer Research UK Country: UK Publications
| Collaborators
|
Detail Information
Publications
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activitySandra J Strauss
Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, W Smithfield, London, United Kingdom
J Clin Oncol 24:2105-12. 2006..07). CONCLUSION: Bortezomib demonstrates encouraging efficacy in MCL in heavily pretreated individuals. Response was associated with a reduction in plasma TNF-alpha and in vitro sensitivity in a small number of patients...- Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high doseMichelle L Harrison
Department of Medicine, Royal Marsden Hospital, London, United Kingdom
J Clin Oncol 25:4542-9. 2007..We performed two sequential phase II studies of infliximab, an anti-TNF-alpha monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC... - Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseFrances Balkwill
Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, EC1M 6BQ London, United Kingdom
Cancer Cell 7:211-7. 2005 - The significance of cancer cell expression of the chemokine receptor CXCR4Fran Balkwill
Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, London EC1M 6BQ, UK
Semin Cancer Biol 14:171-9. 2004..However CXCR4 plays major roles in embryogenesis, homeostasis and inflammation. This raises questions concerning the specificity of CXCR4 antagonists in the treatment of cancer... - Cancer and the chemokine networkFran Balkwill
Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, Charterhouse Square, London EC1M 6BQ, UK
Nat Rev Cancer 4:540-50. 2004 - Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial TrustF Balkwill
Cancer Research UK, Queen Mary s School of Medicine and Dentistry, EC1M 6BQ London, UK
Eur J Cancer 39:1818-27. 2003..In particular, we highlight the potential of international collaborations in translating laboratory science into useful clinical interventions... - Immunology for the next generationFran Balkwill
Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
Nat Rev Immunol 5:509-12. 2005..This article is a personal account of one scientist's experience of communicating biomedical science to young people... - Chemokine biology in cancerFran Balkwill
Cancer Research UK, Translational Oncology Laboratory Barts, The London Charterhouse Square, Queen Mary s Medical School, London EC1M 6BQ, UK
Semin Immunol 15:49-55. 2003..Detailed study of chemokine and chemokine receptor antagonists in experimental cancer models is warranted. Manipulation of the tumor chemokine network could have therapeutic potential in malignant disease... - TNF-alpha in promotion and progression of cancerFrances Balkwill
Institute of Cancer and the CR UK Clinical Centre, Barts and The London, Queen Mary s School of Medicine and Dentistry, 3rd Floor, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
Cancer Metastasis Rev 25:409-16. 2006..This article will discuss the involvement of TNF-alpha in the inflammatory network that contributes to all stages of the malignant process, and consider the possibility that TNF-alpha may be a target for cancer therapy... 
Tumour necrosis factor and cancerFrances Balkwill
Centre for Cancer and Inflammation, Institute of Cancer, Barts, UK
Nat Rev Cancer 9:361-71. 2009..Now that links between inflammation and cancer are appreciated, is TNF a target or a therapeutic in malignant disease -- or both?..- Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer modelS Dias
Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
Int J Cancer 75:151-7. 1998..Comparison of IL-12 and IFN-gamma suggests that sustained induction of IP-10 and activation of a resulting cellular infiltrate may be key changes in regressing tumours... - Cancer and inflammation: implications for pharmacology and therapeuticsF Balkwill
Centre for Cancer and Inflammation, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Clin Pharmacol Ther 87:401-6. 2010..Smoldering, nonresolving inflammation is a component of the tumor microenvironment. The linkage between inflammation and cancer, first perceived in the nineteenth century, is now part of an accepted paradigm of carcinogenesis... - IL-12 regulates VEGF and MMPs in a murine breast cancer modelS Dias
Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
Int J Cancer 78:361-5. 1998..Thus, we suggest that at least 2 mechanisms are involved in IL-12 regulation of angiogenesis, removing the pro-angiogenic stimulus and blocking the release and activity of MMPs... 
Inflammation and cancer: a double-edged swordThorsten Hagemann
Centre for Translational Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
Cancer Cell 12:300-1. 2007..Apetoh et al. describe how activation of innate immunity after conventional radiation or chemotherapy can trigger protective antitumor immunity...- A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cellsN F Li
The Centre for Cancer and Inflammation, Institute of Cancer and the Cancer Research UK Clinical Centre, Barts and the London School of Medicine and Dentistry, London, UK
Oncogene 28:773-80. 2009..On the basis of these findings, we suggest that CSF1R may be a critical factor facilitating hTERT immortalization of epithelial cells... - Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesisR J Moore
Biological Therapy Laboratory, Imperial Cancer Research Fund, London, UK
Nat Med 5:828-31. 1999..Strategies that neutralize TNF-alpha production may be useful in cancer treatment and prevention... - Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumoursC Scotton
ICRF Translational Oncology Laboratory, St Bartholomew s and Royal London School of Medicine and Dentistry, Science Building, Charterhouse Square, London EC1M 6BQ, UK
Br J Cancer 85:891-7. 2001..The leukocyte infiltrate may contribute to tumour growth and spread by providing growth survival factors and matrix metalloproteases. Thus, CCR1 may be a novel therapeutic target in ovarian cancer... - Cancer. Sex, cytokines, and cancerToby Lawrence
Centre for Translational Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
Science 317:51-2. 2007 - The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cellsHagen Kulbe
Centre for Translational Oncology, Institute of Cancer and the Cancer Research UK Clinical Centre and Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, United Kingdom
Cancer Res 67:585-92. 2007.... - Cancer-related inflammationAlberto Mantovani
Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Nature 454:436-44. 2008..The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment... - A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancerSrinivasan Madhusudan
Cancer Research United Kingdom Medical Oncology Unit, University of Oxford, The Churchill, Oxford Radcliffe Hospitals, Headington, Oxford, United Kingdom
Clin Cancer Res 10:6528-34. 2004.... - Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancerSrinivasan Madhusudan
Cancer Research UK Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford, United Kingdom
J Clin Oncol 23:5950-9. 2005..CONCLUSION: We provide evidence for the biologic activity and safety of etanercept in recurrent ovarian cancer. Our data suggest possible clinical activity that must be confirmed in future studies... - Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Alan Ashworth
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
Gynecol Oncol 108:652-7. 2008..As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors... - RalB signaling: a bridge between inflammation and cancerAlberto Mantovani
Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano and University of Milan, Italy
Cell 127:42-4. 2006..In tumor cells the RalB/TBK1 pathway inhibits apoptosis and in nontumorigenic cells it stimulates an innate immune response... - Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanomaDavid J Propper
Imperial Cancer Research Fund Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford X3 7LJ
Clin Cancer Res 9:84-92. 2003..The durable and long-lived responses, clear demonstration of tumor MHC up-regulation, and low toxicity suggest that weekly IFN-gamma 100 microg/m(2) would be a useful addition to chemoimmunotherapeutic regimens...